Latest news with #RST
Time of India
6 days ago
- Health
- Time of India
40% of cases at RST Hospital are head & neck cancers
Nagpur: Ahead of World Head and Neck Cancer Day on Sunday, RST Cancer Hospital in Nagpur revealed a worrying local trend: Head and neck cancers (HNC) account for 40% of all cancer cases diagnosed at the hospital over three years. Tired of too many ads? go ad free now The hospital's data, collected from 2020 to 2023, showed that of the 8,327 cancer patients registered, 3,316 had head and neck cancer. As many as 75% of these patients were men and most suffered from oral cavity cancer. The RST team shared the figures to mark the annual awareness day observed globally on July 27, which aims to educate the public about cancer. The hospital will be observing this day on Saturday as July 27 is Sunday. Dr Kartar Singh, head of Radiotherapy at RST Cancer Hospital and principal investigator of its Hospital-based Cancer Registry, said that delayed diagnosis remains a major hurdle, especially in rural and semi-urban populations. "Late-stage diagnosis is one of the most significant threats our community faces. People often arrive at the hospital only when the disease is advanced, which severely limits treatment options," he said. The study, led by research scientist Dr Revu Shivkala, also showed that men were 60% more likely to be affected than women. Besides oral cavity cancers, other rising sites included the pharynx, larynx, thyroid, brain, and even regions like the nose and neck. Tobacco is the single largest risk factor, contributing to nearly 75% of all HNC cases in India. Other contributors include areca nut (supari) chewing, alcohol, and infections like HPV and EBV. Tired of too many ads? go ad free now Dr BK Sharma, advisor and principal investigator of the Population-Based Cancer Registry (PBCR) at RST, emphasised the importance of prevention and early intervention. "Cancer doesn't have to be a death sentence. With community education, screening, and early treatment, we can drastically reduce mortality," he noted. Nagpur has shown a rise in HNC cases among women, as per recent registry trends underlining the need for awareness even among populations traditionally considered as low-risk groups. Dr Harish Kela, joint director at RST, called for urgent community-level interventions. "The rising trend is alarming. We must focus on school and village-level awareness, regulate tobacco access, and empower healthcare workers to identify early symptoms," he said. BOX WORLD HEAD & NECK CANCER DAY EVENTS TODAY Rashtra Sant Tukdoji (RST) Cancer Hospital and Research Centre will observe World Head & Neck Cancer Foundation Day on July 26, from 9.30am to 11am at its premises. Dignitaries including GMCH Dean Dr Raj Gajbhiye, Dr Devendra Mahore, Sanjay Agarwal, and Thyroid Man of India Dr Madan Kapare will attend. The programme is being held in collaboration with IMA Nagpur, Hedgewar Blood Bank, Lions Club of Medicos, and others.
Yahoo
06-06-2025
- Politics
- Yahoo
Local legislators back tribe's declaration of emergency
PIERRE, S.D. (KELO) — Two of South Dakota's lawmakers who represent the area have written a formal letter of support for the state of public safety emergency declared by the Rosebud Sioux Tribe president. Mitchell residents against Davison County prison site Democratic Rep. Eric Emery and Republican Rep. Rebecca Reimer signed the letter sent June 2 to RST President Kathleen Wooden Knife. Letter-to-Pres.-Wooden-Knife-for-State-of-Emergency-1Download President Wooden Knife's May 27 proclamation follows previous emergency declarations in August 2019 and August 2024. The current proclamation is featured on the Rosebud Sioux Tribe government website and cites 'pervasive law and order and public health issues related to the epidemic of meth and illicit drug use, drug trafficking, and gun related violence and other violent and unlawful activity creating severe and extreme threats to public safety, the health and welfare of the general public.' In her proclamation, President Wooden Knife calls on the U.S. government, the U.S. Department of Justice, the U.S. Department of the Interior and the federal Bureau of Indian Affairs 'to honor their legal, statutory, trust and treaty obligations to provide sufficient resources for competent law enforcement patrol, reporting and investigations (of) criminal activity.' The letter from Emery and Reimer thanks Wooden Knife and says they are honored to stand beside her effort. Emery, a member of the Rosebud Sioux Tribe, represents the southern portion of the legislative district that includes the Rosebud Indian Reservation, while Reimer represents the district's northern part. 'We commend your decisive leadership in addressing this crisis and your administration'swillingness to take action in a time of immense difficulty. It takes courage to confront suchchallenges head-on, and your focus on protecting your people is both necessary anddeeply respected,' their letter states. 'As representatives of our communities, made up of families, elders, first responders,educators, and caregivers, we understand that this crisis reaches far beyond public impacts the well-being of the people in every way and calls for a unified, sustainedresponse rooted in compassion, cultural respect, and community-focused action,' the letter continues. U.S. Sen. Mike Rounds, a former governor of South Dakota, has been pushing the federal government for a second tribal law enforcement training center to be placed somewhere in the Great Plains region. Then-Gov. Kristi Noem, a Republican, provided funding last year for some tribal law officers to receive training through a state course conducted under the state Office of Attorney General. She later held a summit on tribal law enforcement and urged then-U.S. Attorney General Merrick Garland, a Democrat, to take action on tribal public safety. Noem had been temporarily banned from all nine reservations in South Dakota after a speech to the Legislature last year in which she said drug cartels were using reservations as protection and for other remarks that tribal leaders said were offensive. Noem in turn called for law enforcement agreements between tribal and state governments. The Oglala Sioux Tribe, which neighbors the Rosebud reservation, has twice sued the federal government over inadequate law enforcement on the Pine Ridge Indian Reservation. Rounds also recently called for creation of a federal commission on violent crimes committed on tribal reservations. Republican U.S. Rep. Dusty Johnson, who holds South Dakota's lone U.S. House seat, in March urged that 'waste, fraud, and abuse of funds for Indian country' be examined by the federal government. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Time of India
30-05-2025
- Health
- Time of India
Tobacco use accounts for over half of cancer patients in Nagpur
Nagpur: City's RST Cancer Hospital, which houses the cancer registry of the region, revealed alarming data ahead of World No Tobacco Day 2025. From 2021 to 2023, the hospital registered 16,079 cancer patients, and of these, a staggering 56% were found to be tobacco-related cases. Tired of too many ads? go ad free now Oral cancer alone accounted for 2,770 cases — nearly one in every three patients — making it the most common cancer type reported at the hospital. "This is not just a medical problem; it's a public health crisis," said Dr Revu Shivakala, research scientist at RST Cancer Hospital. "The highest number of cases are in the 51-60 age group, but what's worrying is the growing number in the 41-50 bracket. Oral cancer is strongly linked to tobacco and gutkha use, which are still widely consumed in Central India." As the city marks World No Tobacco Day on May 31, doctors from RST Hospital are joining the global call to protect youth from the deceptive strategies of the tobacco industry. The 2025 theme declared by WHO is 'Unmasking the Appeal: Exposing Industry Tactics on Tobacco and Nicotine Products'. "Bright packaging, fruity flavours, and social media influencers are being used to make tobacco look cool to children and teenagers. We must act now," said Dr Vikas Dhanorkar, additional director at RST Cancer Hospital. India's law against tobacco — the COTPA Act 2003 — bans advertising, smoking in public, and sales to minors or near schools. However, experts say enforcement is still patchy, especially in semi-urban areas around Nagpur and other parts of Vidarbha. Dr BK Sharma stressed, "Tobacco continues to claim lives and destroy futures. On this day, we urge everyone to recognise the risks behind marketing and protect our youth from addiction." Tired of too many ads? go ad free now According to WHO, over 37 million children worldwide (aged 13-15) use tobacco, with India alone contributing around 14.6%. Many begin with flavoured products like mint and mango, unaware of the long-term health damage. "Tobacco is not just a bad habit — it's a killer in disguise," warned Dr Kartar Singh, head of radiology at RST. "Let's speak the truth and work together for a tobacco-free tomorrow." Doctors are urging citizens in Nagpur and across Central India to stay alert to how the tobacco industry is targeting the next generation — and to help break the cycle by creating awareness, supporting education, and encouraging tobacco users to seek help in quitting. Cancer Types & Age Trends at RST Cancer Hospital Registry Total Registered Cancer Cases: 16,079 Tobacco-Linked Cases: 9,140 (≈56%) Top 3 Cancer Types Oral Cancer: 2,770 cases (30%) Breast Cancer: 1,330 cases (15%) Cervical Cancer: 1,172 cases (13%) Age Group Most Affected 51–60 years: 26% of total cases 41–50 years: 17% 31–40 years: 13% 61–70 years: 12%
Business Wire
30-05-2025
- Health
- Business Wire
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company's Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This first-of-its-kind technology offers a truly novel approach to treating patients with BTK CLTI disease. Share The Spur Stent System is the first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel compliance and reduce vessel recoil effect. Results of the recently concluded DEEPER REVEAL clinical trial (NCT05358353) to evaluate the Reflow Medical Spur Stent System for below-the-knee (BTK) treatment of chronic limb-threatening ischemia (CLTI), demonstrated that following predilatation, the Spur Stent System achieved a 99.2% technical success 1 rate and 97.0% freedom from MALE 2 and POD 3 at 30 days. 'Clinical data submitted to the FDA demonstrated the safety and efficacy of the Spur Stent System,' said Mahmood K. Razavi, MD, FSIR, FSVM, who serves as Director of the Clinical Trials and Research Center at St. Joseph Heart and Vascular Center in Orange, California. 'This novel device will be a valuable and innovative expansion of our treatment toolbox as a unique device for the treatment of complex BTK disease,' he added. S. Jay Mathews, MD, MS, FACC, FSCAI, the Cath Lab Director at Bradenton Cardiology/Manatee Memorial Hospital in Bradenton, Florida, commented, 'It's exciting to see the clinical success of the DEEPER REVEAL trial enabling the De Novo clearance of the Spur Stent System. This first-of-its-kind technology offers a truly novel approach to treating patients with BTK CLTI disease. As an adjunct to standard balloon angioplasty, Spur RST enables us to address this complex disease in a more effective way, achieving these outcomes that go beyond what PTA alone can deliver.' Both Dr. Mathews and Dr. Razavi were lead Principal Investigators for the study, which was conducted at 49 centers in the U.S. and enrolled 130 patients. 'Extensive research and development, which laid the groundwork for the DEEPER REVEAL trial, enabled the creation and clinical validation of the Spur Stent System, an innovative mechanical endovascular device engineered to enhance lesion penetration and optimize the treatment of BTK peripheral arterial disease,' said Teo Jimenez, Senior Vice President of R&D at Reflow Medical. According to Reflow Medical CEO and Co-Founder, Isa Rizk, 'The FDA's De Novo clearance, following positive clinical trial results in patients with CLTI, enables us to provide physicians with an effective therapeutic option for this growing patient population. We are fully prepared to launch our innovative technology through our dedicated sales force, ensuring it promptly reaches physicians to support patients.' The FDA decision will be available on their website under DEN240048. About Reflow Medical, Inc. Reflow Medical is a global company that partners with leading physicians to develop innovative technologies addressing unmet clinical needs in the endovascular treatment of complex cardiovascular disease. The company's portfolio includes coronary and peripheral microcatheters, crossing catheters, and a revolutionary system known as Retrievable Scaffold Therapy (RST). Products include the CoraCatheters line, available in the U.S. only; the Wingman™, Spex ® and Spex LP, available in the U.S., CE Mark and CE Mark-accepting countries and selected markets; and the Spur ®. Spur received CE Mark approval for the treatment of restenotic lesions in below-the-knee arteries, when used in conjunction with a commercially available drug-coated balloon. Reflow Medical is headquartered in San Clemente, California. 1. Technical success defined as less than 30% residual stenosis by visual estimation; 2. Major adverse limb events; 3. Perioperative death
Yahoo
30-05-2025
- Business
- Yahoo
FDA Grants De Novo Clearance for Reflow Medical's Spur® Peripheral Retrievable Stent System
SAN CLEMENTE, Calif., May 30, 2025--(BUSINESS WIRE)--Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company's Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. The Spur Stent System is the first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel compliance and reduce vessel recoil effect. Results of the recently concluded DEEPER REVEAL clinical trial (NCT05358353) to evaluate the Reflow Medical Spur Stent System for below-the-knee (BTK) treatment of chronic limb-threatening ischemia (CLTI), demonstrated that following predilatation, the Spur Stent System achieved a 99.2% technical success1 rate and 97.0% freedom from MALE2 and POD3 at 30 days. "Clinical data submitted to the FDA demonstrated the safety and efficacy of the Spur Stent System," said Mahmood K. Razavi, MD, FSIR, FSVM, who serves as Director of the Clinical Trials and Research Center at St. Joseph Heart and Vascular Center in Orange, California. "This novel device will be a valuable and innovative expansion of our treatment toolbox as a unique device for the treatment of complex BTK disease," he added. S. Jay Mathews, MD, MS, FACC, FSCAI, the Cath Lab Director at Bradenton Cardiology/Manatee Memorial Hospital in Bradenton, Florida, commented, "It's exciting to see the clinical success of the DEEPER REVEAL trial enabling the De Novo clearance of the Spur Stent System. This first-of-its-kind technology offers a truly novel approach to treating patients with BTK CLTI disease. As an adjunct to standard balloon angioplasty, Spur RST enables us to address this complex disease in a more effective way, achieving these outcomes that go beyond what PTA alone can deliver." Both Dr. Mathews and Dr. Razavi were lead Principal Investigators for the study, which was conducted at 49 centers in the U.S. and enrolled 130 patients. "Extensive research and development, which laid the groundwork for the DEEPER REVEAL trial, enabled the creation and clinical validation of the Spur Stent System, an innovative mechanical endovascular device engineered to enhance lesion penetration and optimize the treatment of BTK peripheral arterial disease," said Teo Jimenez, Senior Vice President of R&D at Reflow Medical. According to Reflow Medical CEO and Co-Founder, Isa Rizk, "The FDA's De Novo clearance, following positive clinical trial results in patients with CLTI, enables us to provide physicians with an effective therapeutic option for this growing patient population. We are fully prepared to launch our innovative technology through our dedicated sales force, ensuring it promptly reaches physicians to support patients." The FDA decision will be available on their website under DEN240048. About Reflow Medical, Inc. Reflow Medical is a global company that partners with leading physicians to develop innovative technologies addressing unmet clinical needs in the endovascular treatment of complex cardiovascular disease. The company's portfolio includes coronary and peripheral microcatheters, crossing catheters, and a revolutionary system known as Retrievable Scaffold Therapy (RST). Products include the CoraCatheters line, available in the U.S. only; the Wingman™, Spex® and Spex LP, available in the U.S., CE Mark and CE Mark-accepting countries and selected markets; and the Spur®. Spur received CE Mark approval for the treatment of restenotic lesions in below-the-knee arteries, when used in conjunction with a commercially available drug-coated balloon. Reflow Medical is headquartered in San Clemente, California. 1. Technical success defined as less than 30% residual stenosis by visual estimation; 2. Major adverse limb events; 3. Perioperative death View source version on Contacts Jennifer Carlylejcarlyle@ 949-481-0399
